Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2019

Open Access 01-04-2019 | Research Article

Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis

Authors: N. Wei, B. Zhang, Y. Wang, X. H. He, L. C. Xu, G. D. Li, Y. H. Wang, G. Z. Wang, H. Z. Huang, W. T. Li

Published in: Clinical and Translational Oncology | Issue 4/2019

Login to get access

Abstract

Purpose

To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM).

Methods

We conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin (raltitrexed group), and 20 received TACE using FUDR, oxaliplatin, and pirarubicin (FUDR group). The objective response rate (ORR), disease control rate (DCR), overall survival (OS, from the first TACE), progression-free survival (PFS, from the first TACE), and adverse reactions were evaluated and compared between the two groups, and prognostic factors for OS were analyzed.

Results

The ORRs of the raltitrexed group and FUDR group were 67.2 and 45.0%, respectively (P = 0.076), and the DCRs were 86.9 and 80.0%, respectively (P = 0.452). The median OS (from first TACE) was 14.0 months in the raltitrexed group and 13.0 months in the FUDR group (P = 0.556). The median PFS (from first TACE) was 2.1 months in the raltitrexed group and 2.4 months in the FUDR group (P = 0.878). Univariate and multivariate analyses showed that the primary tumor site, Child–Pugh class, and combination with local ablation (RFA or CRA) were independent significant factors affecting survival. There were no significant differences in adverse reactions between the two groups (P > 0.05), and no treatment-related death occurred in either group.

Conclusion

TACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM.
Literature
1.
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed
3.
Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23:2038–48.CrossRefPubMed
4.
Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.CrossRefPubMedPubMedCentral
5.
6.
Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33(16):1809–24.CrossRefPubMed
7.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15.CrossRefPubMed
8.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRefPubMed
9.
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.CrossRefPubMed
10.
Grothey A, Marshall JL, Seery TE. Current options for third-line treatment of metastatic colorectal cancer. Clin Adv Hematol Oncol. 2016;14(3 Suppl 3):1–15.PubMed
11.
12.
Massmann A, Rodt T, Marquardt S, Seidel R, Thomas K, Wacker F, et al. Transarterial chemoembolization (TACE) for colorectal liver metastases—current status and critical review. Langenbecks Arch Surg. 2015;400(6):641–59.CrossRefPubMed
13.
Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117:343–52.CrossRefPubMed
14.
Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology. 2009;250:281–9.CrossRefPubMed
15.
Ghanaati H, Mohammadzadeh V, Mohammadzadeh A, Firouznia K, Mohammadzadeh M, Motevali M, et al. Efficacy of transarterial chemoembolization on lesion reduction in colorectal liver metastases. Acta Med Iran. 2012;50:535–40.PubMed
16.
Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steele G Jr, Perry LJ, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997;40:770–5.CrossRefPubMed
17.
Li C, Gu Y, Zhao M, Yuan Y, Wang F, Wang Z, et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer Chemother Pharmacol. 2014;74:1079–87.CrossRefPubMed
18.
Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol. 2002;29:119–25.CrossRefPubMed
19.
Balch CM, Urist MM. Intraarterial chemotherapy for colorectal liver metastases and hepatomas using a totally implantable drug infusion pump. Recent Results Cancer Res. 1986;100:234–47.CrossRefPubMed
20.
Schwartz SI, Jones LS, McCune CS. Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg. 1985;201:560–7.CrossRefPubMedPubMedCentral
21.
Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer. 2002;1:179–80.
22.
Feliu J, Castanon C, Salud A, Mel JR, Escudero P, Pelegrin A, et al. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer. 2005;93:1230–5.CrossRefPubMedPubMedCentral
23.
Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol. 1998;16:2943–52.CrossRefPubMed
24.
Vyzula R, Kocakova I, Demlova R, Kiss I, Dusek L, Jarkovsky J. Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer. Neoplasma. 2006;53:119–27.PubMed
25.
Gravalos C, Salut A, Garcia-Giron C, Garcia-Carbonero R, Leon AI, Sevilla I, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012;14:606–12.CrossRefPubMedPubMedCentral
26.
Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol. 2002;13:716–20.CrossRefPubMed
27.
Seitz JF, Bennouna J, Paillot B, Gamelin E, Francois E, Conroy T, et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol. 2002;13:1072–9.CrossRefPubMed
28.
Santini D, Massacesi C, D’Angelillo RM, Marcucci F, Campisi C, Vincenzi B, et al. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase II study. Med Oncol. 2004;21:59–66.CrossRefPubMed
29.
Liu Y, Wu W, Hong W, Sun X, Wu J, Huang Q. Raltitrexed-based chemotherapy for advanced colorectal cancer. Clin Res Hepatol Gastroenterol. 2014;38:219–25.CrossRefPubMed
30.
Guo JH, Zhang HY, Gao S, Zhang PJ, Li XT, Chen H, et al. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World J Gastroenterol. 2017;23:1406–11.CrossRefPubMedPubMedCentral
31.
de Takats PG, Kerr DJ, Poole CJ, Warren HW, McArdle CS. Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer. 1994;69:372–8.CrossRefPubMedPubMedCentral
32.
Cercek A, Boucher TM, Gluskin JS, Aguilo A, Chou JF, Connell LC, et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol. 2016;114:655–63.CrossRefPubMedPubMedCentral
33.
Takahashi H, Akyuz M, Aksoy E, Karabulut K, Berber E. Local recurrence after laparoscopic radiofrequency ablation of malignant liver tumors: results of a contemporary series. J Surg Oncol. 2017;115:830–4.CrossRefPubMed
34.
Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15:2757–64.CrossRefPubMed
35.
Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opin Drug Saf. 2014;13:113–29.CrossRefPubMed
Metadata
Title
Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis
Authors
N. Wei
B. Zhang
Y. Wang
X. H. He
L. C. Xu
G. D. Li
Y. H. Wang
G. Z. Wang
H. Z. Huang
W. T. Li
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 4/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1942-0

Other articles of this Issue 4/2019

Clinical and Translational Oncology 4/2019 Go to the issue

Research Article

Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer

Research Article

Relapse patterns in patients with local and regional cutaneous melanoma

Research Article

Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study

Research Article

Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer

Research Article

Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1

Research Article

Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits